Literature DB >> 17849641

The ethics of withdrawal from study participation.

Elisa J Gordon1, Thomas R Prohaska.   

Abstract

We investigated whether consent forms adhere to Federal Common Rule regulations pertaining to withdrawal from research, described the language of withdrawal provisions, and assessed differences in studies by withdrawal provisions. A random sample of 114 consent forms from a midwestern, academic medical center were examined for descriptive content of withdrawal parameters stated within consent forms. All consent forms included the required statement about withdrawal pursuant to the Code of Federal Regulations (CFR) 45 CFR (46.116(a)(8)), and all adhered to regulation 45 CFR (46.116(b)(4)) by including a statement that withdrawal will have no affect on care provided. Of 114 studies, thirty (26%) studies explicitly requested subjects/participants to engage in a further behavior before withdrawing from the study. Safety was mentioned in only 4 (13%) instances as the reason for an additional visit or test. None of the consent forms provided information about the consequences to the subject's health or well being by withdrawing from study participation. Consent forms generally conform to current regulations. Future research should examine subjects' experiences of withdrawing from research in order to help clinical investigators and Institutional Review Boards (IRBs) assess the extent to which consent forms indicate barriers to withdrawal and for compliance with Federal Common Rule regulations.

Entities:  

Mesh:

Year:  2006        PMID: 17849641      PMCID: PMC9527709          DOI: 10.1080/08989620600848645

Source DB:  PubMed          Journal:  Account Res        ISSN: 0898-9621            Impact factor:   3.057


  29 in total

1.  Making informed consent meaningful.

Authors:  B A Brody
Journal:  IRB       Date:  2001 Sep-Oct

2.  Empirical research on informed consent with the cognitively impaired.

Authors:  Gavin W Hougham; Greg A Sachs; Deborah Danner; Jim Mintz; Marian Patterson; Laura W Roberts; Laura A Siminoff; Jeremy Sugarman; Peter J Whitehouse; Donna Wirshing
Journal:  IRB       Date:  2003 Sep-Oct

3.  Variation in Institutional Review processes for a multisite observational study.

Authors:  Catherine C Vick; Kelly R Finan; Catarina Kiefe; Leigh Neumayer; Mary T Hawn
Journal:  Am J Surg       Date:  2005-11       Impact factor: 2.565

4.  Two models of implementing informed consent.

Authors:  C W Lidz; P S Appelbaum; A Meisel
Journal:  Arch Intern Med       Date:  1988-06

5.  Trust, The fragile foundation of contemporary biomedical research.

Authors:  N E Kass; J Sugarman; R Faden; M Schoch-Spana
Journal:  Hastings Cent Rep       Date:  1996 Sep-Oct       Impact factor: 2.683

6.  Quality of informed consent in cancer clinical trials: a cross-sectional survey.

Authors:  S Joffe; E F Cook; P D Cleary; J W Clark; J C Weeks
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

7.  Retention of minority participants in clinical research studies.

Authors:  Colleen S Keller; Adelita Gonzales; K Jill Fleuriet
Journal:  West J Nurs Res       Date:  2005-04       Impact factor: 1.967

8.  Motivational techniques for improving compliance with an exercise program: skills for primary care clinicians.

Authors:  Robert Scales; Joseph H Miller
Journal:  Curr Sports Med Rep       Date:  2003-06       Impact factor: 1.733

9.  Minimizing attrition in a long-term clinical trial of pediatric asthma.

Authors:  Bruce G Bender; Misoo C Ellison; Melanie Gleason; James R Murphy; D A Sundstrom; Stanley J Szefler
Journal:  Ann Allergy Asthma Immunol       Date:  2003-08       Impact factor: 6.347

10.  Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy.

Authors:  Z A Nurgat; W Craig; N C Campbell; J D Bissett; J Cassidy; M C Nicolson
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

View more
  3 in total

1.  Withdrawal from biobank research: considerations and the way forward.

Authors:  Kristina Hug; Göran Hermerén; Mats Johansson
Journal:  Stem Cell Rev Rep       Date:  2012-12       Impact factor: 5.739

2.  Addressing missing data in clinical trials.

Authors:  Thomas R Fleming
Journal:  Ann Intern Med       Date:  2011-01-18       Impact factor: 25.391

3.  Data retention after a patient withdraws consent in clinical trials.

Authors:  André P Gabriel; Charles P Mercado
Journal:  Open Access J Clin Trials       Date:  2011-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.